Clinical trial
Tocladesine in Treating Patients With Recurrent or Refractory Multiple Myeloma
NCT00004902 · Northwestern University, Other · Completed
Key facts
| NCT number | NCT00004902 |
|---|---|
| Title | Tocladesine in Treating Patients With Recurrent or Refractory Multiple Myeloma |
| Official title | Phase II Pilot Evaluation of Infusional 8 Cl-cAMP in the Treatment of Relapsed or Refractory Multiple Myeloma |
| Lead sponsor | Northwestern University, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Multiple Myeloma and Plasma Cell Neoplasm |
| Intervention type | Drug |
| Interventions | tocladesine |
| Start date | Jan 1, 1998 |
| Primary completion | Nov 1, 1999 |
| Completion | Nov 1, 1999 |
| First posted | Jul 26, 2004 |
| Last update posted | May 30, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: